A scalable synthesis of 7-hydroxy cannabidiol (7-OH CBD), a primary metabolite of (-)-cannabidiol (CBD), is highly desirable, from an industrial point of view, to enable future clinical trials. A Piers-Rubinsztajn reaction was key to enable a mild deprotection and a concise synthesis of 7-OH CBD from commercially available CBD, in 31% overall yield.A Piers-Rubinsztajn reaction was key to enable a mild deprotection and a concise synthesis of 7-hydroxy cannabidiol from commercially available cannabidiol, in 31% overall yield.
A scalable synthesis of 7-hydroxy cannabidiol (7-OH CBD), a primary metabolite of (−)-cannabidiol (CBD), is highly desirable, from an industrial point of view, to enable future clinical trials. A Piers–Rubinsztajn reaction was key to enable a mild deprotection and a concise synthesis of 7-OH CBD from commercially available CBD, in 31% overall yield.
Piers–Rubinsztajn reaction to unlock an 8-step synthesis of 7-hydroxy cannabidiol
Cocco, Emanuele;Iapadre, Debora;Brusa, Alessandro;Pesciaioli, Fabio
;Carlone, Armando
2024-01-01
Abstract
A scalable synthesis of 7-hydroxy cannabidiol (7-OH CBD), a primary metabolite of (-)-cannabidiol (CBD), is highly desirable, from an industrial point of view, to enable future clinical trials. A Piers-Rubinsztajn reaction was key to enable a mild deprotection and a concise synthesis of 7-OH CBD from commercially available CBD, in 31% overall yield.A Piers-Rubinsztajn reaction was key to enable a mild deprotection and a concise synthesis of 7-hydroxy cannabidiol from commercially available cannabidiol, in 31% overall yield.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
